For the quarter ending 2025-09-30, CCCC made $11,230K in revenue. -$32,049K in net income. Net profit margin of -285.39%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue from collaboration agreements | 11,230 | 6,463 | 7,238 | 4,108 |
| Restructuring | - | - | - | 609 |
| Research and development | 25,989 | 26,197 | 27,072 | 27,523 |
| General and administrative | 8,920 | 8,767 | 9,330 | 10,331 |
| Impairment of long-lived assets | 10,733 | - | - | - |
| Restructuring | 0 | 0 | - | - |
| Total operating expenses | 45,642 | 34,964 | 36,402 | 39,072 |
| Loss from operations | -34,412 | -28,501 | -29,164 | -34,964 |
| Interest and other income, net | 2,246 | 2,481 | 2,842 | 3,563 |
| Total other income, net | 2,246 | 2,481 | 2,842 | 3,563 |
| Loss before income taxes | -32,166 | -26,020 | -26,322 | -31,401 |
| Income tax expense | - | - | - | 44 |
| Net loss | -32,166 | -26,020 | -26,322 | -31,467 |
| Unrealized loss on marketable securities | - | -73 | -10 | -327 |
| Unrealized gain on marketable securities | 117 | - | - | - |
| Comprehensive loss | -32,049 | -26,093 | -26,332 | -31,794 |
| Net loss per share basic (in dollars per share) | -0.44 | -0.37 | -0.37 | -0.455 |
| Net loss per share diluted (in dollars per share) | -0.44 | -0.37 | -0.37 | -0.455 |
| Weighted-average number of shares used in computed net loss per share basic | 72,563,311 | 71,005,743 | 70,833,044 | -34,532,228 |
| Weighted-average number of shares used in computed net loss per share diluted | 72,563,311 | 71,005,743 | 70,833,044 | -34,532,228 |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)